DNA-chimeric antigen receptor T cells for immunotherapy
US12338459B2 · kind B2 · utility
0Cited by
4References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 4, 2019 |
| Grant date | Jun 24, 2025 |
| Priority date | — |
| Expiry date | Jun 29, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In certain embodiments, this disclosure provides methods to generate DNA, RNA and/or DNA-peptide nanostructures based chimeric antigen receptor (CAR) T cell (engineered T cell) for cancer immunotherapy, and compositions made by these methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.